ACADIA Pharmaceuticals Inc. (ACAD) Earnings
ACADIA Pharmaceuticals Inc. is expected to report next earnings on August 5, 2026 (in NaN days), with a consensus EPS estimate of $0.06. ACAD has beaten EPS estimates in 8 of its last 12 reported quarters (average surprise +320.8% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 6, 2026 | $0.04 | $0.02 | -50.0% | $268M | -4.3% |
| Feb 25, 2026 | $0.12 | $1.60 | +1233.3% | $284M | -2.9% |
| Nov 5, 2025 | $0.14 | $0.26 | +85.7% | $279M | -4.8% |
| Aug 6, 2025 | $0.14 | $0.16 | +14.3% | $265M | +1.0% |
| May 7, 2025 | $0.10 | $0.11 | +10.0% | $244M | +2.2% |
| Feb 26, 2025 | $0.13 | $0.17 | +30.8% | $260M | -4.9% |
| Feb 27, 2024 | $0.30 | $0.28 | -6.7% | $231M | +3.2% |
| Nov 2, 2023 | $-0.43 | $-0.40 | +7.0% | $212M | -5.7% |
| Aug 2, 2023 | $-0.12 | $0.01 | +108.3% | $165M | +4.7% |
| Feb 27, 2023 | $-0.25 | $-0.26 | -4.0% | $136M | +1.7% |
| Nov 2, 2022 | $-0.18 | $-0.17 | +5.6% | $131M | -5.8% |
| May 4, 2022 | $-0.49 | $-0.70 | -42.9% | $115M | -5.3% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · May 6, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
Catherine mentioned Acadia delivered a solid start to the year with total revenue growth. Debut had strong growth with $101 million in sales, 20% year-over-year, and successful launch of Debut Sticks. New Plaza had $167 million in sales, 6% year-over-year growth, with referral growth and normalized refill dynamics. Pipeline updates included approaching phase two readout for remnifanserin in Alzheimer's disease psychosis and accelerated phase three study in Japan for tropinotide. Tom discussed Debut's strong quarter, launch of Debut Sticks with positive feedback. Liz provided R&D updates, including progress on pipeline programs. Mark reviewed financial results, including revenue, expenses, and cash position.
Guidance
Reaffirmed 2026 net sales guidance for both Debut and New Plaza. Expect total revenue to be back-end loaded with greater sales contribution from both brands in the second half of the year driven by expanded New Plaza Field Force and broader availability of debut sticks. Full year 2026 total revenues expected to be 1.22 to 1.28 billion.
Segment performance
Total revenue for the first quarter was $268 million, up 11% compared to adjusted total revenue in the first quarter of 2025. Debut had revenue of $101 million, representing 20% year-over-year growth. New Plaza generated $167 million of net product sales in the first quarter, representing 6% growth year over year on an adjusted basis.